Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:56 PM
Ignite Modification Date:
2025-12-24 @ 1:56 PM
NCT ID:
NCT04994795
Eligibility Criteria:
Inclusion Criteria:
* Adult ≥18 years old
* Patient diagnosed with Stage IV NSCLC (de novo or earlier stage progression to stage IV)
* Absence of oncogene activating mutations eligible patients to targeted therapy (EGFR, ALK)
* Cohort A: Received first line treatment with pembrolizumab monotherapy
* Cohort B: Received first line treatment with chemotherapy and pembrolizumab combination therapy
* Cohort C: Received first line treatment with chemotherapy doublet
Exclusion Criteria:
* Prior anti-cancer therapy for actual stage IV NSCLC
* Critical data missing (e.g., PD-L1 status, baseline millimetric imaging, first evaluation millimetric imaging)
* Patients participating in other clinical trials that modify the standard of care
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04994795
Study Brief:
Protocol Section:
NCT04994795